Tag: all-time-high

The Nasdaq Biotechnology index fell 23 percent in the first three months of 2016, its worst quarterly performance since 2002, and remains down one-third from its all-time high, reached last July. Andy Acker, a portfolio manager at Janus Capital Group who helps oversee $7 billion in healthcare assets, says the sell-off led to a steep…